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Abstract
Emergence Agitation is a frequent complication in the pediatric postoperative population;
with up to 80% incidence (Stamper, Hawks, Taicher, Bonta & Brandon, 2014). These
patients will present with crying, overexcitement, thrashing, agitation and is seen within
the first 30 minutes of emergence of general anesthesia (Mohkamkar, Farhoudie, AlamSahebpour, Mousavi, Khani & Shamomhammadi, 2014). Dexmedetomidine, a selective
alpha 2 agonist, reduces norepinephrine output, initiates firing of inhibitory neurons such
as the gama aminobutric acid system and reduces release of substance P and other
catecholamines. These actions provide the patient with sedation, analgesia, and anesthesia
(Nagelhout & Elisha, 2018). Due to the mechanism of action of dexmedetomidine,
bradycardia and hypotension have been seen in pediatric patients. This has put a limit on
the use of dexmedetomidine in this population. The purpose of this systematic review was
to examine efficacy and side effects of various doses of dexmedetomidine to prevent
emergence agitation in the pediatric postoperative patient. A comprehensive literature
review was completed with the use of CINAHL Plus with full text, PubMed and Google
Scholar. Preferred Reporting Items for Systematic Meta-Analysis (PRISMA), was used as
guidelines to assist in proper identification of articles. The quality and critical appraisal of
each randomized control trial was determined by the Critical Appraisal for Summaries of
Evidence (CASE) worksheet. A cross study analysis table was created and used to analyze
results of all studies. The findings of this systematic review determined dexmedetomidine
was beneficial in emergence agitation prevention. Dexmedetomidine dosed at 0.5 mcg/kg1mcg IV boluses and 1 mcg/kg – 2 mcg/kg intranasal sprays provided good relief with
limited adverse effects.
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Dexmedetomidine Use in the Pediatric Postoperative Patient with Emergence Agitation:
A Systematic Review
Background/Statement of the Problem
Emergence agitation, also known as emergence delirium, is a common phenomenon
in postoperative pediatric patients after receiving anesthesia, specifically sevoflurane or
desflurane anesthesia (Garg et al., 2018). Emergence agitation can happen in any patient
at any age but has been found to occur three to eight times more commonly in pediatric
patients (Stamper et al., 2014). The incidence of emergence agitation is the highest in
children who are younger than six years old, have a history of anxiety, specifically
preoperative anxiety, and experience a fast emergence from general anesthesia (Stamper
et al., 2014). Emergence agitation is defined as “a mental disturbance during the
recovery from general anesthesia consisting of hallucinations, delusions, and confusion
manifested by moaning, restlessness, involuntary physical activity, and thrashing about in
bed” (Stamper et al., p. 480). Sevoflurane, an anesthetic commonly used in general
surgery, is found to have the highest incidence of emergence agitation in pediatrics (Peng
& Zhang, 2015).
The child with emergence agitation presents with restlessness, combative
movements, thrashing, confusion, and may be inconsolable (Zhu, Wang, Zhu, Niu, &
Wang, 2015). All of these factors may cause discomfort to the patient, parents, postoperative registered nurses (RNs) and anesthesia providers. Emergence agitation also
puts the patient at risk for self-injury including wound dehiscence and dangerous removal
of various medical catheters that may be in place in the post-operative phase (Stamper et
al., 2014).
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The etiology of emergence agitation is uncertain; it may be related to pain,
behavioral issues, anxiety, surgical type, character of patient, and the anesthesia used
(Kim, Kim, Yoon, & Kil, 2015). One such sedative is dexmedetomidine, which is a
highly specific alpha 2 agonist that produces a calming effect. It relieves anxiety without
effecting the respiratory drive, which makes this medicine very beneficial for pediatric
patients (Garg et al., 2018). The effectiveness of dexmedetomidine may be based on its
unique pharmacological characteristics. It has been found to be useful in emergence
agitation in adults as well (Garg et al., 2018). There is lack of labeling on the use of
dexmedetomidine in pediatrics, but some literature suggests that it may be favorable for
the pediatric population.
According to Mahmoud and Mason (2015), dexmedetomidine is found to be
advantageous in decreasing emergence agitation in pediatric patients in the perioperative
phase due to many factors such as neuro-protection, anxiolysis, analgesia, sympatholytic,
and lack of respiratory depression. The intraoperative administration of dexmedetomidine
has been shown to reduce emergence agitation in pediatric patients. Not only does it
provide analgesia and anxiolysis but the use of dexmedetomidine intraoperatively can
decrease the amount of anesthetics used, which in itself may be a triggering agent for
emergence agitation. (Kim et al., 2015). According to Qiao, Xie, and Jia (2017),
dexmedetomidine has beneficial effects preoperatively, intraoperatively, and
postoperatively in pediatric patients.
There seems to be no common protocol for preventative measures or even
diagnosis of emergence agitation (Stamper et al., 2014). Dexmedetomidine has been
identified as a useful preventative measure (Kim et al., 2015). Other preventive measures
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include comfort measures and small doses of fentanyl (Nagelhout & Elisha, 2018). The
purpose of this paper was to conduct a systematic review to examine the efficacy and side
effects of various doses of dexmedetomidine to prevent emergence agitation in the
pediatric postoperative patient.
Next, the review of the literature will be presented.

4
Literature Review
The principal databases used to perform this systematic review included CINAHL
Plus with full text, PubMed, and Google Scholar. The keywords used included
emergence agitation, sevoflurane, dexmedetomidine, intraoperative, and pediatrics. The
time period of the search was limited to ten years.
Emergence Agitation/Delirium
Emergence agitation, also known as emergence delirium and post anesthetic
excitation, can occur in patients of any age. It was first described in the 1960s in a
retrospective research study performed on patients who received general anesthesia. This
study reviewed 14,436 cases and discovered the incidence of emergence agitation was
highest in childhood, decreased in middle aged patients, and had a slight increase in the
elderly (Eckenhoff, Kneale & Dripps, 1961). This highest incidence of emergence
agitation in children remains true to this day. It is a frequent problem in the pediatric post
anesthetic care unit. The incidence of pediatric emergence agitation can range from 10 to
80% (Mohkamkar et al., 2014). The large range of pediatric emergence agitation, which
some studies report from 2% to 80%, is most likely due to the differing anesthetic
techniques used on children (Stamper et al., 2014). The large range can also be related to
the varying scoring systems used to determine emergence agitation (Dahmani et al.,
2010). About four million children undergo general anesthesia each year and emergence
agitation remains a significant problem (Mohkamkar et al., 2014).
Pediatric emergence agitation is a postoperative occurrence associated with
digressive cognitive and psychomotor ways of acting (Stamper et al., 2014). Examples of
these characteristics include crying, overexcitement, thrashing, and agitation. Emergence
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agitation occurs within the first 30 minutes of emergence from general anesthesia, but it
can last up to two days (Mohkamkar et. al., 2014). Post hospitalization behavioral
changes (PHBC) are also associated with emergence agitation and 73% of children have
been found to have these changes which include sleep disturbance, night terrors,
separation anxiety, and aggression towards providers or caregivers (Pickard, Davies,
Birnie & Beringer, 2014).
Emergence agitation is noted to be one of the major causes of frustration among
parents and medical workers in the postoperative phase (Makkar, Bhatia, Bala, Dwivedi
& Singh, 2016). These characteristics associated with this syndrome can put the patient,
family, and medical staff at risk of injury and can interfere with the child’s recovery time.
The child may be at risk of removing certain medical catheters, dressings, and monitoring
devices needed in the postoperative period and can cause self-harm (Mohkamkar et. al.,
2014). Adverse effects of emergence agitation may be transient but can defer discharge
from the post anesthetic care unit due to the risk of self-injury and injury to family or
caregivers. The extra care required from the nursing team to care for a patient presenting
with emergence agitation may strain nursing resources and cause dissatisfied post
anesthetic care (Costi et al., 2014).
A key way to manage pediatric emergence agitation is to identify the phenomenon
quickly (Stamper et al., 2014). Over the years, there has been a paucity of dependable and
validated scales to measure emergence agitation in pediatrics. The lack of a standardized,
accepted measurement tool contributes to the wide range of incidence of emergence
agitation that is reported in the literature (Stamper et al.). Also, the lack of standardized
measurement tools makes it difficult for providers to find a definite treatment for
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emergence agitation (Stamper et al.). There remains an absence of prophylactic treatment
for emergence agitation. (Costi et al., 2014). Treatment for emergence agitation has been
suggested but no study has found one approach to be superior to the others (Mohkamkar
et al, 2014). The treatment of emergence agitation is still up for debate based on the value
of the interventions. (Stamper et al., 2014).
To determine emergence delirium in adults, medical providers use the Level of
Consciousness-Richmond Agitation and Sedation Scale (LOC-RASS), but it has not been
validated for pediatrics (Stamper et al., 2014). In 2004, the Pediatric Anesthesia
Emergence Delirium (PAED) scale (Table 1) was developed due to the lack of standard
of care regarding emergence agitation.
Table 1
Pediatric Anesthesia Emergence. Delirium Scale

Mohkamkar, M., Farhoudi, F., Alam-Sahebpour, A., Mousavi, S., Khani, S., &
Shamomhammadi, S. (2014). Postanesthetic emergence agitation in pediatric patients
under general anesthesia. Iranian Journal of Pediatrics,24(2), 186.

The PAED scale was created in an attempt to increase knowledge and
communication to prevent unwanted side effects from emergence agitation (Costi et al.,
2014). The PAED scale is more frequently used in studies after 2004 but its use is
inconsistent in clinical practice and in research. It was developed based on a theoretical
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framework of agitation, which focuses on changes in consciousness and cognition; this
aids in distinguishing emergence agitation from pain. The PAED scale consists of five
characteristics that are each scored by using a five-point scale. The five characteristics
consist of the child’s state of consciousness, ability to focus attention, ability to
thoughtfully organize external stimuli, psychomotor behavior, and emotional behavior. A
PAED score higher than or equal to 10 determines the presence of emergence agitation
(Costi et al., 2014).
The PAED scale has been reported to be a more reliable and valid measurement
for pediatric emergence agitation than the LOC-RASS scale (Costi et al., 2014). Stamper
et al. (2014) performed a quality improvement project to evaluate the identification of
pediatric emergence agitation by implementing the use of the PAED scale in the pediatric
PACU. Four hundred patients were assessed using the PAED scale and the LOC-RASS
scale in two different periods, 200 patients in the retrospective audit and 200 patients in
the implementation period. A retrospective chart review was completed using LOCRASS from perioperative electronic health records one year before the implementation
period. A one-year time period was chosen to lessen the influence of education needed
for perioperative staff members. Then data was collected during the implementation of
the PAED scale using LOC-RASS and PAED scale. The incidence of pediatric
emergence agitation in the implementation period with the LOC-RASS scale was 7.5% (n
= 200) and the PAED scale was 11.5% (n = 198), whereas the incidence of emergence
agitation only occurred in about 3% of the retrospective period population. But there was
little difference in acknowledging emergence agitation in the implementation period;
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emergence agitation was assessed in 12 patients with the LOC RASS and the PAED scale
during the implementation period.
Effect sizes (ES) were calculated to establish the clinical significance of the
differences in pediatric emergence agitation of each tool. The incidence between PAED
scale during the implementation period and LOC-RASS during the retrospective was an
ES of 0.79 or 95%. This suggests that the PAED scale was more likely to identify
patients with emergence agitation than the use of LOC-RASS in the retrospective period.
After analysis of all findings, this study suggested that PAED scale is more sensitive in
identifying patients with emergence agitation after emergence of general anesthesia. The
tool allows medical practitioners to better identify patients who are demonstrating a
decrease level of consciousness, restless behavior, or both. The use of LOC-RASS may
lead to false negatives (Stamper et al., 2014).
Emergence Agitation Risk Factors
Although emergence agitation was discovered in the 1960s, the etiology of
emergence agitation is still unknown but various factors can be associated with it
(Makkar et al., 2016). It is important for the anesthesia providers and postoperative
nursing team to identify the risk factors for emergence agitation to manage them
appropriately. The risk factors associated with emergence agitation is highest among
children who are younger than six years of age, have preoperative anxiety, pain, general
anesthesia, rapid emergence from general anesthesia, and head and neck surgery
(Stamper et al., 2014).
Age. Children who are preschool age, younger than six years old, have been
associated with emergence agitation more frequently (Stamper et al., 2014). Overall, the
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pediatric brain is a mirror image of normal age-related regressive processes which cause
a continuous decline in norepinephrine, acetylcholine, dopamine, and gama-aminobutyric
acid (GABA). This puts young children at risk of developing emergence agitation
(Kanaya, 2015). Mokhmakar et al. (2016) stated that children in the age range of 4-6
years old are most sensitive to emergence agitation based on their inability to cope related
to rapid awakening in an unknown environment and psychological immaturity.
Preoperative Anxiety. Children with high anxiety levels at baseline and
preoperative anxiety upon entering the operating room have been linked to emergence
agitation (Stamper et al., 2014). Up to 65% of pediatric patients receiving anesthesia for
surgical procedures will develop extreme fear and anxiety in the pre-operative unit and
during induction of anesthesia (Kain et al., 2004). It also has been noted that children
with anxiety during inhalation induction have a higher incidence of emergence agitation
(Kanaya, 2015). The anxiety can be linked to separation anxiety, fear of anesthesia,
surgery, the setting, and outcome of procedure (Kain et al.). Also, children with
emotional, behavioral, and impulsive personality disorders will have a higher incidence
of emergence agitation (Kanaya, 2015).
Pain. Inadequate pain relief can cause extreme agitation in children if no
interventions are provided. Pain can actually mimic the emergence agitation
phenomenon. It is very important to determine if pain is the cause of agitation or if
emergence agitation is actually present. This is further complicated by the fact that
assessing pain in the pediatric patient can be very challenging as is. The PAED scale
includes a section regarding pain to help determine the presence of emergence agitation
versus pain (Costi et al., 2014). Although pain can be associated with agitation in
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children, many studies have found that in procedures not associated with pain, the child
may still present with emergence agitation, especially if the patient has received
sevoflurane anesthesia (Kanaya, 2015). For example, in many ophthalmologic cases
where no postoperative pain is present and the child received sevoflurane, emergence
agitation presented (Kanaya). Therefore, with lack of pain, emergence agitation still
presents (Mokmahkar et al., 2014).
General Anesthesia. Inhalation of anesthetics are used to provide general
anesthesia. This is considered an “altered physiological state characterized by reversible
loss of consciousness, analgesia, amnesia, and some degree of muscle relaxation”
(Butterworth, Mackey, & Wasnick, 2018). The first anesthetics originated in the 1800’s;
with advanced technology and pharmacokinetics new anesthetics have been derivated
from the original anesthetics with more ideal properties and side effects. The two most
commonly used anesthetics include desflurane and sevoflurane. Desflurane is an
inhalation anesthetic first introduced in 1993 and sevoflurane was introduced in 1995 in
the United States (Nagelhout & Elisha, 2014). The increased use of sevoflurane and
desflurane in medically advanced countries are associated with emergence agitation
(Dahmani et al., 2010)
Desflurane is halogenated with fluorine and has a low solubility in blood and
body tissues. This ensures that a very rapid induction and emergence of anesthesia may
occur (Butterworth, Mackey, & Wasnick, 2018). Multiple studies suggest that desflurane
is associated with emergence agitation due to the rapid induction and recovery time
(Bedaway, 2018). But there is very little data on what drugs to use to prevent emergence
agitation related to desflurane use (Makkar et al, 2016). Although desflurane has been
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linked to emergence agitation, sevoflurane has gained more popularity and is used more
routinely in the pediatric population.
Sevoflurane is halogenated with fluorine but has a slightly higher blood solubility.
One benefit of sevoflurane is the non-pungency, less irritation rapid induction and
emergence. These factors make it a great choice for smooth and fast induction and
emergence of pediatric patients (Butterworth, Mackey, & Wasnick, 2018). The child can
easily breathe this anesthetic in by face mask and works very quickly. It will be given
continuously during the surgical procedure to keep the child under general anesthesia. It
is turned off when it is time for the child to wake up. But since sevoflurane’s launch, it
has been associated with emergence agitation, predominately in pediatric patients (Costi
et al., 2014). It has been suggested that sevoflurane anesthesia may cause triggering
events or even a neurotoxic effect in the central nervous system (Costi et al). Sevoflurane
has an epileptogenicity that may be the triggering cause of emergence agitation. (Kanaya
et al., 2013). Although rapid awakening from sevoflurane and painful procedures are
linked to emergence agitation, some studies have found even with a slow awakening from
sevoflurane anesthesia and nonpainful procedures, pediatric patients present with
emergence agitation (Na, Song, Hwang, Do, & Oh, 2012).
Rapid Emergence. Emergence agitation is precipitated by rapid emergence from
anesthesia and short acting volatile anesthetics, specifically sevoflurane. Rapid
emergence may cause a dissociative state, so when children awaken from anesthesia in
this state they will present with altered cognitive perception (Dahmani, et al., 2010). Kim
et al. (2015) performed a meta-analysis of randomized controlled trails (RCTs) to
investigate the incidence and severity of emergence agitation related to the use of
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desflurane and sevoflurane anesthetics. They reviewed 12 RCTs with a total of 1127
patients. Five hundred and eighty-eight patients received desflurane anesthesia and 608
received sevoflurane anesthesia. Eight studies include patients in the age range of one
year to eight years old, while the four studies include children over the age of ten.
Overall, they found that sevoflurane and desflurane both had equivalent incidences of
emergence agitation at 1.21 and with low heterogeneity, even with desflurane having a
more rapid awakening time than sevoflurane.
Surgery Type. Otorhinolaryngological, ophthalmological, abdominal, and
orthopedic surgical procedures have been closely linked to emergence agitation.
(Mohkamkar et al., 2014). In fact, any surgery involving the head and neck are associated
with increased risk of developing emergence agitation (Stamper et al, 2018). The specific
physiological compromise during these surgeries increase the risk (Zhu et al., 2015).
Otorhinolaryngological and ophthalmological surgeries were discovered to be risk factors
of emergence agitation in the 1960s. It was described as a “sense of suffocation” while
the patient awakened from anesthesia; there is no randomized controlled trials to backing
this hypothesis (Kanaya, 2015).
A study performed by Mohkamkar et al. (2014) compared the prevalence of
emergence agitation in 134 children aged three to seven years. Each child underwent an
elective surgical procedure, either an otorhinolaryngological surgical procedure,
abdominal surgery, orthopedic surgery, urology surgery, or ophthalmic surgery. Out of
all five surgeries, otorhinolaryngological surgical procedures had the highest incidence of
emergence agitation. A significant relationship between the site of operation, specifically
the head and neck, and occurrence of emergence agitation (P<0.05) was found.
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Otorhinolaryngological surgeries were linked to higher pain and increased anxiety with
induction (Mohkamkar et al).
Prevention of Pediatric Emergence Agitation
Emergence agitation puts the pediatric patient at risk of harm to self and delay of
recovery time. It also requires extra care and monitoring from the medical and nursing
staff and can put them at risk of injury as well. The patient’s family or caregivers may be
dissatisfied and upset regarding the emergence agitation and blame the symptoms on the
anesthetic management (Costi et al., 2014). Preventative measures will be required,
which include pharmacological, physical restraint, or comfort measures. The most
frequent preventative measure is pharmacological (Costi et al). The patient cannot be
discharged until the emergence agitation has subsided and the patient is safe.
Pharmacologic Management. Frequently used medications for emergence
agitation treatment are mainly opioids and sedatives. Some of these drugs may have
adverse effects on the patient and may delay recovery and discharge time for the patient.
(Costi et al., 2014). Frequently used drugs to help prevent or stop the incidence of
emergence agitation include midazolam, ketamine, dexmedetomidine, fentanyl,
remifentanil, NSAIDs, and propofol boluses (Costi et al.). Each pharmacological
intervention has different molecular mechanisms that can influence the patients’
outcomes. For example, a bolus of fentanyl during induction of anesthesia has been
shown to reduce the incidence of emergence agitation, but it has negative side effects
such as respiratory depression and retching (Kanaya, 2015).
Mohkmakar et al. (2014) performed a cross sectional descriptive and analytic
study on 747 pediatric patients aged 3-7 who underwent general anesthesia to determine
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the associated risk factors and prevalence of emergence agitation in pediatric patients
undergoing general anesthesia. Mohkmakar et al. (2014) found that midazolam, a
benzodiazepine that provides amnesia and anxiolysis, was used as a premedication for
some patients in this study and no increased incidence of EA was found with this use of
this sedative medication. Propofol and ketamine was used intraoperative with the
anesthetic sevoflurane and there was lack of incidence related to the use of both of these
as well.
The choice of the anesthetic can prevent emergence agitation as well. Another
anesthetic option for children is the use of propofol. Propofol is a 2, 6-diisopropyl phenol.
It has rapid distribution after intravenous bolus dose to brain and high perfused organs.
This leads to rapid induction and rapid reawakening after sedative and anesthetic doses
(Nagelhout & Elisha, 2018). The use of propofol for induction has not been proven to
reduce emergence agitation, but the use of it after induction has been shown to reduce
emergence agitation (Kanaya, 2015). A meta-analysis compared the use of sevoflurane in
560 patients and the use of propofol in 548 patients. This study found that 95% of the
patients had lower incidence of emergence agitation with the use of propofol (Kanaya et
al., 2013).
Dexmedetomidine has been linked to a large reduction in risk of EA (Costi et al.,
2014). In one study it was found to be the most appropriate intervention in preventing
sevoflurane- related emergence agitation (Kanaya, 2015). Costi et al. (2014) performed a
systematic review regarding involved 137 studies and 14,045 children. Participants
included children under the age of 18 years old who were to receive general anesthesia.
The children were separated into two groups based on alternative general anesthesia
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versus use of sevoflurane and use of sevoflurane versus sevoflurane with an adjunct. This
systematic review found that propofol, halothane, dexmedetomidine, opioids, and
ketamine all reduce the risk of EA. Thirty-four studies compared sevoflurane and
halothane for risk of emergence agitation; all studies found the use of halothane has a
lower risk of emergence agitation compared to sevoflurane. Propofol at the end of
anesthesia was used in five studies; 1mg/kg boluses were administered at the end of
anesthesia and showed a decrease in emergence agitation. One study used 3 mg/kg bolus
of propofol for induction and showed no effect on the risk of emergence agitation, along
with another study who used 2-2.5 mg/kg bolus and found no reduction of emergence
agitation as well. Ketamine as oral premedication was found to reduce overall risk of
emergence agitation in two studies, where as one study found no reduction of emergence
agitation with the use of ketamine after induction of anesthesia. Three other studies did
find that ketamine as a 0.25mg/kg bolus at the end of anesthesia reduces the risk of
anesthesia. Twelve studies showed an overall decrease in risk of emergence agitation
with the use of IV fentanyl. Twelve studies investigating this intervention found a
significant reduction in the risk of EA (RR 0.37, 95%). Another added four studies found
that after dexmedetomidine was used there was a lower risk of emergence agitation as
well (Costi et al.)
Use of Dexmedetomidine to Prevent Pediatric Emergence Agitation
Background. Dexmedetomidine, also known as precedex, is part of the imidazole
class and is an alpha 2 agonist with a short half-life. It is a freely soluble in water with a
ph of 4.5-7.0 and is preservative free (Nagelhout & Elisha, 2018) and it is administered
via intravenous infusion. Alpha 2 receptors are G-protein-coupled receptors, when
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activated by dexmedetomidine, inhibit calcium channels, activate potassium channels,
and provide direct modulation of the exocytic release of proteins, which produces
hyperpolarization of cells and inhibit cells (Nagelhout & Elisha, 2018).
Dexmedetomidine’s alpha 2 receptor mediated side effects are generated by its effect in
the locus ceruleus and spinal cord. The main site of action of this medication is at the
pontine noradrenergic nucleus in the locus ceruleus. Dexmedetomidine provides a
sedative effect by binding to the alpha 2 receptors in the locus ceruleus, reducing
norepinephrine output and initiating the firing of inhibitory neurons such as the gama
aminobutric acid system. Dexmedetomidine also binds to the alpha 2 receptors found in
the dorsal horn and supra-spinal sites, which reduces the release of substance P and
reduces the release of other catecholamines (Pickard et al., 2014).
Dexmedetomidine has sedative, analgesic, and cardiovascular sympatholytic
actions, is an anxiolytic, and reduces post-operative shivering (Nagelhout & Elisha,
2018). It is used commonly in anesthesia and intensive care (Bedirli et al., 2017).
Dexmedetomidine can be used intraoperatively and is known to reduce intravenous and
inhaled anesthetic use in the operating room. It also can be used outside of the operating
room to help with anxiety and analgesia. The use of dexmedetomidine is approved for up
to 24 hours for sedation in a critical care unit, as well as sedation for short term surgical
procedures (Nagelhout & Elisha, 2018). Dexmedetomdiine has been found useful in the
pediatric perioperative period to help control emergence agitation. It enhances the
tolerance, weaning of narcotics and lessens the amount of sedation needed for
mechanically ventilated patients (Nagelhout & Elisha, 2018).
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Dexmedetomidine produces a stage 2 non rapid eye movement sleep through
initiation of the endogenous sleep-promoting pathway. It will induce a conscious
sedation; the patient can be drowsy yet arousable (Zhu et al., 2015). A unique
characteristic of dexmedetomidine is that it has little to no respiratory depression. This is
beneficial because dexmedetomidine will provide analgesia with lack of respiratory
depression (Pickard et al., 2014). The brain respiratory center is able to remain responsive
to carbon dioxide levels and airway patency and the airway reflexes are present as well. It
produces a sedation that is similar to patients’ natural sleep while they remain easily
arousable. The medication does not change cerebral metabolism but decreases cerebral
blood flow because of cerebral vasoconstriction. A neuroprotective effect has also been
noted. The dose of dexmedetomidine can be given via bolus 1 mcg/kg over 1- minute
followed by an infusion at 0.2-0.7 mcg/kg/hr (Butterworth, Mackey, & Wasnick, 2018).
Although dexmedetomidine has unique benefits, it does have some unwanted side
effects. It may cause bradycardia and decrease blood pressure due to its sympatholytic
effects. It has been reported to cause sinus arrest after a bolus dose of dexmedetomidine
in some pediatric patients. It also may cause transient hypertension with rapid initial
loading doses or high maintenance doses due to vasoconstriction. Dose dependent
hypotension is considered normal in this drug (Nagelhout & Elisha, 2018). These
cardiovascular effects are from the stimulation of CNS alpha receptors and systemic
vasodilation that ensues. There is a reduction in myocardial oxygen demand which
provides an antianginal effect (Nagelhout & Elisha). These hemodynamic side effects
cause providers to limit the use of it in anesthesia pediatric practice (Bedirli et al., 2017).
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Prevention of Emergence Agitation. There is a lack of recommendations
regarding what medications to use to prevent emergence agitation. Some studies suggest
the use of fentanyl, midazolam, ketamine, NSAIDs, alpha 2 agonists, and/or propofol. As
discussed above, dexmedetomidine has many pharmacological benefits that other
pharmacological agents do not, such as a conscious sedation, analgesia, anxiolysis, and it
also does not cause respiratory depression. The literature related to dexmedetomidine for
the use of prevention of emergence agitation is abundant. Many RCTs do expose the fact
the dexmedetomidine can be beneficial, but some studies found side effects of
dexmedetomidine may outweigh the preventative emergence agitation benefits.
Kim et al. (2015) conducted a randomized control trail to study the appropriate
dose of dexmedetomidine, given the reported side effects of prolonged sedation and
cardiovascular complications associated with administration. Twenty-one children
participated in the study, all between the ages of 2 and 12 years old, all undergoing either
a tonsillectomy, adenoidectomy, or both procedures. All patients received general
anesthesia for the procedure, were maintained with desflurane, and dexmedetomidine was
given intravenously before the start of surgery. A scale called the Emergence Agitation
Scale, developed by Cole et al. (2002), was used to detect emergence agitation. Kim et al.
(2015) chose this scale based on its previous use in identifying emergence agitation with
the use of dexmedetomidine. A score of greater than 4 or 5 was considered positive for
emergence agitation. In the event that a patient experienced emergence agitation, a 0.1
mcg/kg dose of dexmedetomidine greater than the one before would be administered. If
no emergence agitation was experienced, the dose of dexmedetomidine would be
decreased by 0.1 mcg/kg. They used the Dixon’s up and down sequential method to
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determine threshold of amount of increase or decrease of medication administered. If a
patient had a pain score > 8 or needed rescue medication for emergence agitation they
would give nalbuphine 0.1 mcg/kg.
Nine patients developed emergence agitation. They all received nalbuphine 0.1
mcg/kg, the 50% effective dose (0.25mcg/kg) of dexmedetomidine, and the 95%
effective dose (0.38mcg/kg) of dexmedetomidine. Cardiovascular symptoms, such as
bradycardia or hypotension, did not occur in any of the children upon administration of
dexmedetomidine. This may be due to the fact that intubation and a bolus dose of 0.2
mg/kg of atropine occurred after the administration of dexmedetomidine, so stimulation
prevented the cardiovascular complications. Prolonged sedation was not observed with
participants who received dexmedetomidine. This could be contributed to the fact that the
doses were smaller compared to other studies (Kim et al., 2015).
Makkar et al. (2016) performed a study comparing 100 patients who randomly
received either 0.3 mcg.kg of dexmedetomidine, 1 mg/kg propofol, or 0.9% saline 15
minutes before the end of surgery. The patients were between the ages two and eight
years, American Society of Anesthesiologist (ASA) physical status of 1 or 2 and
scheduled for general anesthesia with a single-shot caudal block for elective infraumbilical surgery. No premedication was given to the children, the parents were present
for induction, and sevoflurane was used for inhalation induction. The PAED scale was
used and a score of 10 or more was consistent with diagnosis of emergence agitation.
Emergence agitation was found in 9.4% (n = 32) of children who received
dexmedetomidine intraoperatively, 13.9% (n = 36) of children who received propofol,
and 40.6% (n = 32) of children who received saline. Although dexmedetomidine was
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found to be most effective in preventing emergence agitation, it was associated with
longer sedation times and longer extubation times.
A study performed by Bedirliet et al. (2017) compared the use of
dexmedetomidine and tramadol. Seventy- Seven patients were enrolled in this study and
received either dexmedetomidine or tramadol intraoperatively for an adenotonsillectomy
under sevoflurane anesthesia. Each drug was compared based on its hemodynamic
stability, postoperative pain management, control of emergence agitation, and postoperative sedation levels. The authors found that both dexmedetomidine and tramadol
were effective in reducing emergence agitation. Patients received either 1 mcg/kg IV
bolus of dexmedetomidine (Group D; n = 38) or 2 mg/kg IV dose of tramadol (Group T;
n = 39). Tramadol was associated with a lower incidence of nausea and vomiting, and
extubation times were shorter with the use of a tramadol. Dexmedetomidine had higher
incidence of intraoperative bradycardia, hypotension, longer stays in PACU, and
extended sedation times. There was a lack of a placebo group, so the ability to determine
the effectiveness of both drugs was limited. In conclusion, both tramadol and
dexmedetomidine were effective in analgesia control and decreased incidence of
emergence agitation.
In summary, conflicting results related to the use of dexmedetomidine for
prevention of emergence agitation exists and side effects of dexmedetomidine in the
pediatric population exist. The purpose of this review is to conduct a systematic review to
examine the efficacy and side effects of various doses of dexmedetomidine to prevent
emergence agitation in the pediatric postoperative patient.
Next, the theoretical framework will be presented.
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Theoretical Framework
The theoretical framework used to guide this study was Preferred Reporting Items
for Systematic Reviews and Meta-Analysis (PRISMA). Preferred Reporting Items for
Systematic Meta-Analysis provides an evidence-based checklist with 27 items and a fourphase flow diagram. The use of a checklist and flow diagram provide an unequivocal and
complete report of a systematic review (Liberati et al., 2009). This framework helps
spotlight common topics, results, and relationships of variables found throughout RCTs.
The 27-item checklist (Table 1) provides recommendations on what should be reported
regarding the title, abstract, introduction, methods, results, discussions, and findings.
(Liberati et al). After each section of the checklist, obligatory guidelines are found that
help develop a more concise and accurate systematic review.
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Table 1
27 Item Checklist for Preferred Reporting Items for Systematic Reviews and Metaanalysis

The four-phase flow diagram (Figure 1) is used to report the total number of
records found and then the articles excluded along with the reasons for the exclusion. The
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process of trial and selection is shown through this diagram, as well as the eligibility
criteria (Liberati et al., 2009). The flow diagram provides a graphical representation of
the entire process including article identification, screening, eligibility, and what studies
were included in the final study

Figure 1. Four phase flow diagram for preferred reporting items for systematic reviews
and meta-analysis (Liberati et al., 2009)
Overall, PRISMA is very helpful but lacks detail related to the quality
assessment of a randomized control trial. The Critical Appraisal for Summaries of
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Evidence (CASE) worksheet was used to critically appraise the included studies (Foster
& Shurtz, 2013).
Next, the methods will be presented.
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Method
Purpose
The purpose of this paper was to conduct a systematic review to examine the
efficacy and side effects of various doses of dexmedetomidine administration in
prevention of emergence agitation in the pediatric postoperative population.
Outcomes
Outcomes included incidence of emergence agitation and side effects in the
postoperative phase in pediatric patients.
Inclusion/Exclusion Criteria
Inclusion criteria included studies specific to emergence agitation in the pediatric
population; subjects less than eight years old; ASA one or two; the use of an emergence
agitation scale; use of sevoflurane; and the use of only dexmedetomidine for sedation.
Only randomized control trials or systematic reviews from 2009 to 2018 and in English
were utilized.
Exclusion criteria included any studies before 2009; studies that examine adult
subjects; studies that do not use an emergence agitation assessment tool; studies that use
alternative drugs as a placebo; and those not meeting the inclusion criteria.
Search Strategy
Research articles were found via CINAHL Plus with full text, PubMed, and Google
Scholar. A detailed search was conducted using the search terms dexmedetomidine,
sevoflurane, pediatrics, emergence agitation, and intraoperative. The PRISMA flowchart
was utilized to document the process used to select studies for the systematic review.
Data Collection

26
A separate table was formed to summarize selected outcomes of the individual
studies (Table 2).
Table 2
Data Collection Table: Outcomes of the Study

A data collection table was created to summarize each study, including the design,
sample, surgical procedure, and method. (Table 3).
Table 3
Data Collection Table: Study Demographics

Critical Appraisal
The Critical Appraisal for Summaries of Evidence (CASE) worksheet was used
for quality assessment of the evidence provided. The quality of the data gathered from the
studies was determined via the Critical Appraisal for Summaries of Evidence (CASE)
worksheet (Table 4). This tool is used to evaluate quality of evidence and provides a
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standard for evidence-based medicine point of care summaries. It has 10 questions that
explore the specificity, authorship, reviewers, methods, grading, clarity, citations,
currency, bias, and relevancy for each study (Foster & Shurtz, 2013). The answers must
be either “yes”, “no”, or “not completely”. Each study was reviewed, and the ten
questions were answered.

Table 4
Critical Appraisal for Summaries of Evidence (CASE) Worksheet
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Data Synthesis & Cross Study Analysis
The cross-study analysis tool (Table 5) was designed to collect and organize
information from each study. Each column presents a topic to allow for descriptive
information to be placed. This table was used to compare each study based on their
outcomes.
Table 5
Cross Study Analysis Tool

Next, the results will be presented.
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Results
Figure 2 on the next page provides a visual analysis of the search strategy used to
perform this systematic review. The initial search began with “dexmedetomidine” and
“pediatrics”. This search yielded 203 results among selected databases. The search term
“sevoflurane” was added and generated 26 results. Lastly “emergence agitation” was
added to search term and the years were adjusted to 2009-2018; this yielded 17 results.
After the article search was performed, 12 studies were excluded for not meeting the
inclusion criteria listed above. Lastly, the remaining five studies were appraised and
selected to complete this systematic review.

30

Figure 2. Completed PRISMA flow diagram demonstrating article identification,
screening, eligibility, and inclusion (Moher et al., 2009).

Each of the five studies included in this systematic review were reviewed
individually in this section and illustrated in Appendix A and Appendix B. Appendix A
(Tables A1-A6) presents each studie’s demographics and methods used. The main
information in these study tables include purpose, design, sample, surgical procedure, and
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method used. Next, Appendix B (Tables B1-B6) presents study outcomes. The main
information found in these study tables include dexmedetomidine dose, efficacy, adverse
side effects, and limitations. Appendix C presents Critical Appraisal for Summaries of
Evidence (CASE) worksheet. This will aid in assessing for reliability, validity, and
applicability of each study in this systematic review. Appendix D presents the cross-study
analysis tool. Each study is numbered and examined based on emergence agitation
incidence, ASA classification/Patient characteristics, anesthetic used, bradycardia events,
hypotension events, and length of hospital stay.
Individual Studies
A prospective double-blind randomized study performed by Kim et al. (2014)
(Appendix A, Table A1) assessed the effects of dexmedetomidine infusions with
sevoflurane requirements, recovery profiles, and emergence agitation in children
undergoing ambulatory surgery. The surgical procedure consisted of either a hernioplasty
or orchiopexy. A total of 40 children with ASA 1 between the ages 1-5 years old were
included in this study. Children with mental retardation, developmental delay,
neurological or psychiatric illnesses that may be associated with agitation, coagulation
disorder, spinal anomalies or bilateral procedures were excluded. The patients were
selected at random into two groups, Group D and Group S. The parents of the patients
selected remained with the children in the operating room until the child lost
consciousness to decrease preoperative anxiety. Inhalation induction was performed on
each child and an intravenous line was placed. After placement of intravenous line,
Group D received dexmedetomidine and Group S received saline; both received 1
mcg/kg IV bolus over 10 minutes followed by a 0.1 mcg/kg/hr maintenance infusion until
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the end of surgery. Each child also received a caudal block to help with postoperative
pain. ET sevoflurane, mean arterial pressure and heart rate were recorded prior to the
administration of dexmedetomidine or saline, just after loading doses, ten minutes after
loading dose, start of operation and every ten minutes until operation was done.
The patients were then brought to post anesthetic care unit and EA was assessed at
arrival and every 5 minutes for up to 30 minutes in PACU. Emergence Agitation was
assessed with a four-point scale created by Watcha (Kim et al., 2015). Points were given
based on 0= asleep, 1 = calm, 2= crying but can be consoled, 3- crying and unconsolable,
4 = agitated and thrashing. Children with a score of 3 or 4 were determined to have
emergence agitation. Pain and sedation were assessed only with first oral intake,
discharge time, and adverse effects.
Outcomes for this study by Kim et al. (Appendix B, Table B-1) found that
intraoperative dexmedetomidine bolus dose and infusion reduced both anesthetic
requirements and emergence agitation without delaying discharge in pediatric ambulatory
surgery. Emergence agitation was noted to be lower in group D than group S (5% vs
55%, p=0.001). Mean arterial pressure and heart rated were decreased by 22-28% and 1821% in group D compared to group S. Six patients received atropine for bradycardia with
or without hypotension with the dexmedetomidine bolus dose (P=0.020). The discharge
time did not differ between either group (Group D, 201 minutes vs Group S, 207
minutes). There were no adverse effects such as nausea, vomiting, and urinary retention.
Evaluation of the integrity of this study by Kim et al., applied from the CASE
worksheet (Appendix C, Table C-1), suggested that this trial brings an individualized
topic specific to practice. It also found that there wqas transparency related to the authors,
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methods, and observers. The study was approved by IRB and informed consent was done
with each parent. Appropriate exclusion criteria were present. Groups were randomly
assigned by a computer generated system, but they did not name the system. This study
did present with some limitations. First, the authors suggested that uncertainty existed
related to the proper scoring tool for use with EA. Kim et al. (2014) chose the Watcha et
al. EA scale because it included a consolability component. They had concerns that the
approved PAED scale did not apply to children who are asleep in PACU. Second, the
researchers did not assess pain, which has been suggested to interfere with diagnosis of
EA. Each patient did receive a caudal block, so Kim et al. believed pain was not a factor
in this scenario. Last, the sample size calculation for each groups’ dexmedetomidine dose
was based on ET-sevo. ET–sevo, also known as end tidal sevoflurane concentration, tells
the anesthesia provider how much MAC of sevoflurane the patient has. Based on other
studies, Kim et al. (2014), monitored the ET-sevo, to help determine effects of
dexmedetomidine. This suggested that the sample size of 40 patients may have been too
small.
The randomized double-blind study by Di et al. (2017) (Appendix A Table A-2)
evaluated the use of dexmedetomidine with low concentration sevoflurane vs high
concentration sevoflurane and its effect on smooth deep extubation, emergence
characteristics, recovery time, and incidence of airway complications. A total of seventyfive patients, who were either an ASA I or II, and between the ages 3-7 years old, who
underwent an adenotonsillectomy were randomly divided into three groups by a
computer-generated table of numbers. Group D0 consisted of 25 patients who received
intravenous saline 4mcg/ml IV bolus. Group D1 consisted of 25 patients who received
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dexmedetomidine 1 mcg/kg IV bolus over 10 minutes. Group D2 consisted of 25 patients
who received dexmedetomidine 2 mcg/kg IV bolus over 10 minutes. Each group was
maintained on sevoflurane for at least 10 minutes before deep extubation. Following
extubation each patient was placed in a lateral position after adequate spontaneous
ventilation and a patent airway was determined. Patient was then transferred to the
PACU. The PAED scale was used to diagnose EA in the PACU. Emergence Agitation
was defined with a score greater than 10.
Outcomes of this study by Di et al (2017) (Appendix B, Table B-2), demonstrated
that the overall occurrence of emergence agitation was lower with the use of
dexmedetomidine. After extubation no breath holding, laryngospasm, bronchospasm, and
hypoxemia were observed. In the PACU, Group D0 (24%) presented with emergence
agitation and were treated with fentanyl. In Group D1(0%) and Group D2 (0%),
incidence of emergence agitation was significantly less than Group D0 (p=0.05). The
times of discharge from PACU to home were longer in group D0 (33.7) and Group D2
(32.8) compared to Group D1 (25.5). No respiratory complications or nausea/vomiting
were noted in the PACU in all groups.
When evaluating the integrity of this study utilizing CASE questionnaire
(Appendix C, Table C-2), it was noted that the trial presented an individualized topic
specific to practice, transparency related to the authors, methods, reviewers and editors.
Each parent was presented with information and informed consent was obtained. Patients
were randomly assigned into groups with a computer generated table of random numbers.
A research observer was assigned to each patient to evaluate the quality of extubation and
respiratory status. The observer was blinded to drug and groups. The results of this study
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can be applicable to pediatric population undergoing ENT surgery. This study did have
some limitations. The first limitation mentioned by the authors was the lack of plasma
drug levels of dexmedetomidine. Therefore, there was no link between sedation and
hemodynamic changes of dexmedetomidine in blood. Second, each patient was deep
extubated, based on the absence of airway responsiveness and continuation of regular and
spontaneous respiration after laryngopharyngeal suction. Per the Di et al (2017) a benefit
of deep extubation is improved recovery and increase overall comfort. However, the
authors did not take this into consideration when determining emergence agitation, so it is
unclear if this benefitted emergence agitation or make it worse.
The double-blind randomized control trial by Chen, Wang, Huang, and Fu (2018)
(Appendix A, Table A-3) evaluated the efficacy of different doses of DEX as a rapid
bolus to aid in the prevention and treatment of EA in pediatric population. One hundred
children ranked as ASA I or II, between the ages of 3-7 years old were randomly enrolled
into five groups (Random number method was used). The control group was group D1
which received saline IV bolus, group D2 received 0.25 mcg/kg dexmedetomidine IV
bolus, group D3 received 0.50 mcg/kg of dexmedetomidine IV bolus, group D4 received
0.75 mcg/kg of dexmedetomidine IV bolus and group D 5 received 1 mcg/kg of
dexmedetomidine IV bolus. Inclusion criteria was normal intelligence, liver, and kidney
function, scheduled for elective inguinal hernia repair surgery, no allergies to anesthesia,
and entered the operating room without parents. The patients were brought into the
operating room, inhalation induction with sevoflurane was performed and LMAs were
placed once anesthetized. Once stable vital signs were achieved patients received
medications based on what group assignment to. Heart rate, mean blood pressure, and

36
oxygen saturation were recorded before study drug was administered and every 5 minutes
after. When surgery was complete, patients were extubated, and each patient was brought
to the PACU. Emergence agitation, pain, and adverse effects were assessed in PACU.
The PAED scale was used to assess emergence agitation, a score > 12 was a diagnosis of
EA. Propofol 1 mg/kg was given for treatment of EA, if the patient was considered free
of pain and if the parents or caregiver could not console the patient.
Outcomes of this study by Chen et al. (2018) (Appendix B, Table B-3),
demonstrated that the incidence of EA was extremely lower in groups D4 (0%, P <
0.001) and D5 (0%, P < 0.001), and fewer incidences of EA was observed in group D2
(5%, P= 0.096) and D3 (5%, P = 0.096). Emergence agitation was found most commonly
in group D1 (30%). It was noted as the dose of dexmedetomidine increased, the recovery
time increased, but it was not considered a large difference in total adverse events. There
were no large differences in adverse events and bradycardia in all the groups.
Bradycardia was defined as a heart rate decrease by greater than 30% of baseline. Eight
patients had a 30% decrease in heart rate from baseline but did not require treatment. No
patient needed treatment for pain, cough, headache, or vomiting. All patients were able to
breathe spontaneously and maintain their oxygen saturation greater than 98%.
When evaluating the integrity of this study by utilizing the CASE questionnaire
(Appendix C, Table C-3), it suggested that the study presented a focused and clear issue.
Informed consent was done with each patient’s parent and the children were randomly
assigned into groups using the random number method. Patients were excluded if they
had an allergy to dexmedetomidine, G-6-PD deficiency, a history of arrhythmia,
bronchial and cardiovascular disease, abnormal liver function, or a history of use of alpha
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2 receptor agonist or antagonist. No patient received premedication. A BIS monitor was
used to determine adequate anesthesia and then dexmedetomidine doses were
administered at a rate of less than 5 seconds. The results of this study can be applicable to
the pediatric population receiving inguinal hernia repairs. There were some limitations to
this study. First, the study used the PAED scale; the authors noted that the subjective
aspects of this scale may yield differing subjective evaluations by users, though this scale
has been widely used for the use of emergence agitation. Second, the authors failed to
mention if the study staff were blinded to the study drugs or if any personally received
education on the PAED scale. Third, the rate of dexmedetomidine bolus was less than
five seconds; various studies suggested bolus doses be administered over 10 minutes due
to hemodynamic issues. It is unclear if the five second bolus skewed the adverse events
results. Lastly, the sample size was 100 patients from one hospital which rather small and
involving just one hospital. These findings suggest that the grading system was not
completely transparent and translatable and that the summary was not completely
unbiased.
The randomized double-blind clinical trial by He et al. (2013) evaluated the
effects of two different doses of dexmedetomidine infusion on the end tidal concentration
of sevoflurane required for smooth LMA removal and on postoperative recovery
measures such as emergence agitation in pediatric patients. This trial studied eighty-seven
patients with ASA scores of I or II, between the ages of 3-7 years old, who underwent
elective minor surface surgery for less than an hour under general anesthesia. The
patients were randomly assigned to one of three groups. Group C received saline. Group
D1 received dexmedetomidine 0.5 mcg/kg and group D2 received dexmedetomidine 1
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mcg/kg. Each study drug was labeled as study drugs and were prepared by an anesthesia
nurse independent of the study. Patients were brought into the O.R., connected to
appropriate monitoring and preoxygenation and inhalation induction with 8% sevoflurane
was started. Once patient was anesthetized, LMA was placed. The study drug was placed
on an infusion pump and administered as an IV bolus after LMA insertion. After surgery
was complete, LMA removal occurred when the sevoflurane concentration reached 2.2%.
Patients were then transferred to the PACU and kept in the unit until they met an
Aldrete score of 9 or more and were free from nausea and vomiting. The Aldrete score
evaluates a patient’s activity, respirations, circulation, consciousness, and oxygen
saturation. The anesthetist would monitor respiratory complications and emergence
agitation until arrival in PACU. The emergence time and recovery time were recorded in
PACU. Behavior in PACU was recorded by a blinded observer with a 5 point scale; 1 for
sleeping, 2 for awake and calm, 3 for irritable and crying, 4 for inconsolable crying, 5 for
severe restlessness, disorientation and thrashing around. Scores greater than 3 indicated
agitation and the patient received propofol 1 mg/kg if unconsolable. If pain was noted by
complaints or if patient was trying to remove the surgical dressing they received 1
mcg/kg IV.
Outcomes of this study by He et al. (2013) demonstrated that emergence agitation
was lowered with the use of dexmedetomidine. The incidence of emergence agitation was
significantly lower in group D1 (17%) and in group D2 (6%) compared to group C (42%,
P=0.003). But groups D1 and D 2 were comparable (P=0.179). Pain was found to be
similar within all three groups (P=0.719). Hemodynamic issues were noted with a higher
dose of dexmedetomidine (1 mcg/kg, Group D2). The issues did not overstep 20% of the
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values prior to dexmedetomidine infusion. No patients suffered from severe respiratory
complications such as laryngospasm, bronchospasm, or hypoxemia. Breath holding was
found to be lower in group D2 (3%) than in Group C (27%, P=0.009) but comparable
between groups D1 and C (P=0.385). Severe coughing was lowest in Group D1 (14%)
and D2 (6%) as compared to Group C (39%, P=0.005). Groups D1 and D2 were
comparable (P=0.323). Emergence times were prolonged in group D2 and Group C
compared to Group D1 (P=0.014). Lastly, the recovery time was prolonged in Group D2
and Group C compared to Group D1 (P=0.010).
When evaluating the integrity of this study with the CASE questionnaire
(Appendix C, Table C-4), it suggested the study addressed a clear and focused issue
specific to practice and transparency related to the authors and observers. The study was
approved by an ethics committee and each child’s parents received informed consent.
The study used a computer generated numbers system to assign groups. This study was
not completely transparent regarding the research methods transparency and the grading
system transparency. Some limitations were presented in the study. First, all of the
procedures in the study were less than an hour and each patient received either a regional
or local anesthetic block and no opioids were given. If the patient did not receive a type
of block, or if the procedure was long, the outcomes might have been different. Second,
each patient was accepted into the study if they were going to receive minor surface
surgery, but the authors did not elaborate on what specific surgeries were examined. This
may provide some bias. Third, patients that received 2 mcg/kg of dexmedetomidine in the
pilot study were noted to be unarousable and sleepy for a long time after surgery, so the
authors lowered doses in the study. Last, the researchers used an infusion pump to
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administer the dexmedetomidine per the hospital protocol. The period of infusion was 10
minutes and it was unsure if this provided an advantage or not.
The randomized single blinded control study conducted by Lin et al. (2016)
(Appendix A, Table A-5) evaluated the hypothesis that a single premedication dose of
dexmedetomidine could reduce preoperative anxiety and also minimize emergence
agitation in children undergoing cataract surgery, specifically with sevoflurane
anesthesia. Ninety children from the ages 1 to 8 years old, ASA I or II undergoing
cataract surgeries were enrolled in this study. Patients were randomly selected into 3
groups using a computer generated randomization program. Patients in group C received
intranasal saline, Group D1 received 1 mcg/kg of dexmedetomidine, and Group D2
received 2 mcg/kg of dexmedetomidine. A masked research assistant administered
intranasal study drugs 45 minutes before induction of anesthesia and the patient laid
supine for 2 minutes to help with intranasal dexmedetomidine absorption. Anesthesia was
induced via inhalational induction and an LMA was placed. All patients received topical
proparacaine eye drops. After the procedure ended LMA was removed and patient was
transferred to PACU.
On arrival to PACU, the patients were monitored for heart rate, blood pressure,
and oxygen saturations by the PACU nurses. Every 5 minutes the patients were assessed
with the PAED scale and the CHEOPS scale. PAED scores > 10 were considered
emergence agitation. If the PAED score was above 15 the patients were treated with 1
mg/kg of propofol intravenously.
Outcomes of the study by Lin et al. (2016) (Appendix B, Table B-5) suggest that
intranasal dexmedetomidine reduced the incidence of postoperative emergence agitation
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with no delay in emergence time or lack of adverse event. Intranasal dexmedetomidine
greatly reduced emergence agitation in group D 1 23.3% (P<0.001) and group D2 10%
(P<0.001). Emergence agitation was found most commonly in group C 80%. This
suggests a high amount of emergence agitation with just sevoflurane anesthesia. The
emergence time and PACU stay time were comparable among all three groups. Clinically
significant bradycardia, were not observed in any of the patients after the
dexmedetomidine administration. The reductions in heart rate and blood pressure were
found to not be statistically different in Group D1 and Group D2 (P >0.05).
When evaluating the integrity of this study utilizing the CASE questionnaire
(Appendix C, Table C-5) it suggested the study addressed a clear and focused issue.
There was no transparency related to authorship, design, or methods. Set protocols were
used for intranasal dexmedetomidine administration, inhalation and maintenance of
anesthesia, and PACU stay. The authors expressed there was a masked research assistant
who administered the intranasal dexmedetomidine, but failed to say if anesthesia
providers or PACU nurses knew which patients received study drugs. The authors failed
to mention if informed consent was obtained from parents of the patients. Some other
limitations the authors presented included the fact that the influence of resistance of mask
inhalation induction may influence emergence agitation. Finally, the authors failed to find
dose dependent effects of dexmedetomidine related to hemodynamic changes. This
suggests that intranasal routes may affect the bioavailability of dexmedetomidine and
provide some uncertainty.
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Cross-Study Analysis
The cross-study analysis table (Appendix D) illustrates each study by number, the
percentage of emergence agitation found in each study, the characteristics of each patient
population, the type of anesthetic used, and adverse outcomes including; bradycardia,
hypotension, and length of hospital stay. All five studies included patients between the
ages 1-8 years old and ASA I or II. Surgeries varied throughout the studies, including
hernioplasty/orchiopexy (Kim et al., study 1), adentonsillectomy (Di et al., study 2),
inguinal hernia repair (Chen et al., study 3), minor surface surgeries (He et al., study 4),
and cataract surgery (Li et al., study 5). All studies used sevoflurane anesthesia but some
studies included regional anesthesia as well. Study 1 used sevoflurane but also included a
caudal block to disregard postoperative pain and focus on results of emergence agitation.
Study 3 used sevoflurane and ilioinguinal/iliohypogastric nerve blocks in an attempt to
disregard postoperative pain as well. The studies 2 and 4 used sevoflurane anesthesia
with no regional anesthesia. Study 5 used sevoflurane but the authors stated they gave
0.5% proparacaine hydrochloride drops to help with pain postoperatively.
All studies compared various doses of dexmedetomidine to a placebo of saline.
Emergence agitation was assessed in the PACU in all studies. The scale to assess
emergence agitation varied throughout the studies. The PAED was used in study 2, 3, and
5. Study 1 used the Watcha EA scale and Study 4 did not state the scale used.
Overall, the incidence of emergence agitation was decreased with the use of
dexmedetomidine compared to saline. But based on dexmedetomidine dosing, the
presence of emergence agitation varied. In study 1 (Kim et al., 2017), group D received a
1 mcg/kg bolus of dexmedetomidine followed by an infusion of dexmedetomidine of 0.1
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mcg/kg/hr until end of surgery. Only had 5% of emergence agitation was found in Group
D compared to group S with 55% emergence agitation. Group S received saline. In study
2 (Di et al., 2017), Group D1 received 1 mcg/kg bolus and Group D2 received 2 mcg/kg
bolus; both had 0% of emergence agitation. Group D0 received saline which presented
with 6% incidence of emergence agitation.
In study 3 (Chen et al., 2018), group D1 received saline and presented with the
most emergence agitation. Group D 2 received 0.25 mcg/kg bolus of dexmedetomidine
and 5% of patients presented with emergence agitation. Group D3 received 0.5 mcg/kg
IV bolus of dexmedetomidine and 5% presented with emergence agitation. Group D4
received 0.75 mcg/kg IV bolus of dexmedetomidine and no emergence agitation was
experienced. Group D5 received 1 mcg/kg IV bolus of dexmedetomidine and just like
Group D4 0% of emergence agitation was noted. These findings demonstrate that the
groups D4-D5, with doses of dexmedetomidine 0.75mcg/kg-1mcg/kg boluses, were most
effective.
In study 4 (He et al., 2013), group D1 received 0.5 mcg/kg IV bolus of
dexmedetomidine and 17% presented with emergence agitation. Group D2 received 1
mcg/kg IV bolus of dexmedetomidine and 6% experienced emergence agitation. Group C
received saline and there were 42% emergence agitation cases. These findings suggest
the dosing of dexmedetomidine of 1 mcg/kg IV bolus worked the best.
In study 5 (Lin et al., 2016), group C was given saline and had an 80%
occurrence of emergence agitation. In group D1, which received 1 mcg/kg intranasal
dexmedetomidine, 23.3% presented with emergence agitation. Group D2 received 2
mcg/kg of intranasal dexmedetomidine and had a 10% occurrence of emergence
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agitation. These findings suggest that intranasal doses and bioavailability may work
better with higher doses, like group D2, 2 mcg/kg intranasal.
Adverse effects such as hypotension and bradycardia were noted throughout all
five studies. Studies 2 (Di et al., 2017), 3 (Chen et al., 2018), 4 (He et al., 2013), and 5
(Lin et al., 2016) did report hypotension and bradycardia all fell within a 20% decrease of
patients’ baseline. No patient had to be treated in these studies. In study 1, six patients
were noted to have bradycardia with hypotension and without, all of whom received
atropine.
All studies included same day surgeries and no patients had an extended stay due
to dexmedetomidine. Study 1 (Kim et al., 2017), 3 (Chen et al., 2018), and 5 (Lin et al.,
2016) did not note any delays in recovery time. Study 2, group D0 and group D2, had the
longest recovery time in PACU. The authors believed this was due to the higher doses of
dexmedetomidine in group D2 and the use of additional fentanyl for treatment of
emergence agitation in group D0. Study 4 Group D 2 and group C presented with the
longest recovery time in PACU. Group D2 received the highest dose of dexmedetomidine
but group C received saline. Group C was noted to wake up in pain and patients more
commonly received fentanyl, but all went home on the same day.
Next, the summary and conclusions will be presented.
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Summary and Conclusions
Pediatric emergence agitation is a postoperative complication with cognitive and
psychomotor affects (Stamper et al., 2014). The untoward effects of emergence agitation
include crying, overexcitement, thrashing, and agitation (Mohkamkar et al., 2014). The
pediatric patient with emergence agitation is at risk of causing self-harm and harm to
medical staff and family or caregiver. The patient is also at risk of removal of medical
catheters, dressings, and monitoring devices that may be needed postoperatively
(Mohkamkar et al. 2014)). A pivotal way to manage pediatric emergence agitation is to
diagnose it quickly (Stamper et al., 2014).
Dexmedetomidine, an alpha 2 agonist, binds to alpha 2 receptors in the locus
ceruleus, decreases norepinephrine output, and produces analgesia. It also has an
analgesic action by binding to alpha 2 receptors in dorsal spine and super-spinal sites and
decreasing the release of substance P (Pickard et al., 2014). Dexmedetomidine also has an
anxiolytic and reduces post-operative shivering (Nagelhout & Elisha, 2018). Benefits of
dexmedetomidine include conscious sedation, similar to endogenous sleep patterns, and
little to no respiratory depression (Zhu et al., 2015). Dexmedetomidine has been linked to
a large reduction in pediatric emergence agitation. Although it has unique benefits, it
does come with unwanted side effects. It produces sympatholytic effects that may cause
bradycardia, and hypotension. It also may cause transient hypertension with rapid initial
loading doses or high maintenance doses due to vasoconstriction.
The purpose of this systematic review was to examine the efficacy and side
effects of various doses of dexmedetomidine to prevent emergence agitation in the
pediatric postoperative patient. A comprehensive literature review was performed with
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the use of CINHAL Plus with full text, Pub med, and Google Scholar. Keywords used to
perform the search included emergence agitation, sevoflurane, dexmedetomidine,
intraoperative, and pediatrics. The preferred reporting items for systematic reviews and
meta-analyses was used as the theoretical framework and the PRISMA flow diagram was
used to aid in the identification of eligible studies based on inclusion and exclusion
criteria. (Liberati et al, 2009)
A total of five studies met the inclusion criteria. Data tables were created to
illustrate key design components of each study. Then, a table was created to illustrate
outcomes for each study, focusing on dose and efficacy of dexmedetomidine and
incidence of emergence agitation. The Critical Appraisal for Summaries of Evidence
(CASE) worksheet was used to perform a critical appraisal of each study. Last, study
analysis was performed on each individual study that met inclusion criteria. A table was
created to compare emergence agitation incidence, patient characteristics, anesthetic
used, dexmedetomidine dose, hypotension/bradycardia event, and length of stay across
the five studies.
The findings of this systematic review suggest that overall, the use of
dexmedetomidine decreases the incidence of emergence agitation in the pediatric
population. The dose of dexmedetomidine does provide more coverage and efficacy with
rare adverse side effects. The range of bolus doses was from 0.25 mcg/kg to 2 mcg/kg
boluses. In the Kim et al. (2014) study, the researchers started a dexmedetomidine
infusion after the bolus dose. Lin et al. (2016) chose to use the intranasal route instead of
intravenous. Kim et al. (2014) found the dose of 1 mcg/kg IV bolus followed by a 0.1
mcg/kg/min dexmedetomidine infusion reduced the incidence of emergence agitation
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without delaying discharge. Chen et al. (2018) found that 0.75 mcg/kg and 1 mcg/kg IV
bolus dose prevented emergence agitation with transient decrease in heart rate and blood
pressure, but was well tolerated in the pediatric population. He et al. (2018) found the
doses of 0.5 mcg/kg and 1 mcg/kg IV boluses of dexmedetomidine provided the best
relief of emergence agitation with few side effects. Di et al. (2017) administered doses of
1 mcg/kg to reduce emergence agitation with no side effects. This study also found the
efficacy of 2 mcg/kg IV bolus to be useful in emergence agitation reduction, but the
patients presented with prolonged postoperative recovery. Lin et al. (2016) documented
the best efficacy of intranasal doses 1 mcg/kg and 2 mcg/kg of dexmedetomidine in
reduction of emergence agitation with only slight decreases in heart rate and blood
pressure.
Overall, the studies revealed that bradycardia and/or hypotension can occur but
most were within 20-30% of baseline vitals, which was determined to be tolerable in the
pediatric population. The mean length of recovery was noted to be longest in the groups
with the highest dose of dexmedetomidine compared to lower doses or groups who
received saline.
Several limitations were found in this systematic review. First there were only
five studies that fit into the inclusion criteria with a limited number of selectivity. Second,
pediatrics is a specialty population but not all studies were performed in a specialized
children’s hospital. Both of these limitations could affect the generalizability. There were
also several limitation throughout the studies in this review. All of the studies used
sevoflurane for a volatile anesthetic. Two studies, Kim et al. (2014) and Chen et al.
(2018), used nerve blocks and the study by Lin et al.(2016) used proparacaine eye drops.
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Di et al. (2017) and He et al. (2013) used only sevoflurane and not other anesthetics. The
use of these blocks suggests a limitation on the use of dexmedetomidine, potentially
affecting this study results. Lack of blinding was found in some studies. Three studies
included in this systematic review were double blinded (Chen et al., 2018; He et al.,
2013; Kim et al., 2013), one was single blinded (Lin, 2016), and the last study was not
blinded (Di, 2017). For induction of anesthesia, all studies used inhalation mask
induction, but only one study listed it as a limitation. The resistance and anxiety of mask
induction can increase emergence agitation.
Another limitation noted was the length of time of surgeries; in one particular
study, He et al. (2013), all surgeries were less than one hour. All studies diagnosed
emergence agitation, but not all used the same scale. The PAED is the standard tool for
diagnosis of emergence agitation in pediatrics, but some studies did not use this measure.
Only three studies, Di et al, (2014), Chen et al. (2018), and Lin et al. (2016), used the
PAED scale, which suggests a lack of standardized care. Last, four out of five studies
used intravenous dexmedetomidine and one study, Lin et al. (2016), used intranasal
dexmedetomidine. This presented a limitation due to the lack of knowledge of dose
dependent sides effects and the precise bioavailability of the intranasal route.
In conclusion, this systematic review found that dexmedetomidine was beneficial
in emergence agitation prevention. Specific doses of dexmedetomidine provided better
relief of emergence agitation: 0.5 mcg/kg – 1 mcg/kg IV boluses and 1 mcg/kg – 2
mcg/kg intranasal sprays provided the best relieve with limited adverse effects.
Next, the recommendations and implications for advanced nursing practice will
be presented.
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Recommendations and Implications for Advanced Nursing Practice
When pediatric patients undergo general anesthesia, it is a stressful time for the
patient, parents, and even the provider. Upon awakening from general anesthesia, the
pediatric patient can present with emergence agitation, which is yet another stressful
situation for the patient and those directly involved in care. Emergence agitation can be
found in up to 80% of pediatric patients (Makkar et al., 2015). In fact, emergence
agitation is one of the most significant causes of dissatisfaction in parents and healthcare
providers and can even result in physical harm to the child (Makkar et al.). The patient
can present with restlessness, inconsolability, disorientation, delusion, hallucination, selfinjurious behaviors, and memory impairment (Ali & Abdellatif, 2013). Upon transfer to
PACU, the pediatric patient should be comfortable and resemble what they are like in a
natural sleep due to dexmedetomidine. The patients', parents’, and medical teams’
satisfaction are noted to be higher with the use of dexmedetomidine to prevent emergence
agitation. The CRNA must be able to recognize the importance of this. This systematic
review was able to provide a guide for CRNAs on how to make educated decisions
regarding the use, dose, and efficacy of dexmedetomidine in the pediatric population.
The CRNA should be expected to identify a patient who is at risk for emergence
agitation. The CRNA is an essential member of a pediatric patients care inside and
outside of the operating room. The CRNA must know the factors that play a role in
emergence agitation: age; sevoflurane anesthetic; postoperative pain; separation anxiety;
patients’ personal character; and type of surgery (Fang et al., 2016). The incidence of
emergence agitation is highest in pediatric patients who are less than six years old, have

50
preoperative anxiety, and have a rapid emergence from general anesthesia (Stamper et al.,
2014).
The CRNA must realize the importance of preventing and/or diminishing
emergence agitation to help with the patient’s overall outcomes. Prevention and quick
accurate diagnosis are key (Stamper et al., 2014).The use of the standardized tool, the
PAED, is recommended. A PAED score higher than or equal to 10 determines the
presence of emergence agitation (Stamper et al.). The CRNA should ensure proper
education has been given to PACU nursing staff and various other medical staff who care
for pediatric postoperative patients, regarding the use of PAED scale and emergence
agitation itself.
Certified Registered Nurse Anesthetists are held up to a certain expectation on
excellent patient care. Certified Registered Nurse Anesthetists follow policies and
procedures strictly to ensure proper care is given and can play a leadership role in the
development of policy and clinical guidelines. They have the expertise and training to
design and support a policy related to the use of the PAED scale, in order to better ensure
quick diagnosis and a treatment plan for emergence agitation. The information from this
systematic review can be used to improve the care CRNAs provide and how the CRNA
can educate and support other team members centered in perioperative and postoperative
care. In order to support nursing education, the CRNA can design, implement, and
evaluate additional educational tools and programs regarding emergence agitation itself,
interventions, and diagnosis. Collaboration with the surgeon, anesthesia team, and
nursing teams regarding emergence agitation is key with an emphasis on continuity of
care.
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The CRNA must know pharmacological interventions for emergence agitation.
All studies in this systematic review support the use of dexmedetomidine in prevention of
emergence agitation. Dexmedetomidine is a great choice for pharmacological
intervention. It is an alpha 2 agonist that provide sedative, analgesic, and anxiolytic
effects and also lacks respiratory depression. The CRNA can administer
dexmedetomidine in the perioperative period. Intravenous bolus doses range are
recommended from 0.5-1mcg/kg, based on how patient tolerates it. If the patient does not
have an IV, the anesthesia provider can use 1– 2 mcg/kg intranasal dose to prevent
emergence agitation as well.
The CRNA must also recognize the mechanism of action of dexmedetomidine
and the proper treatment of any potential side effects. The CRNA must be mindful of
each patients’ individual characteristics when administering dexmedetomidine. All
studies in this systematic review have validated that adverse effects from
dexmedetomidine are minimal in pediatrics. But the CRNA must be aware of appropriate
treatment if patient were to become bradycardic or hypotensive; studies have shown that
atropine should be given if vital signs remain below more than 20% of baseline and
remain there. Recognition of a patients’ characteristics and swift action related to adverse
effects based on evidence based knowledge is part of the critical thinking that CRNAs
must be held too.
Although all five studies in this systematic review suggest minimal adverse
effects in pediatrics, no study examined patients with any comorbidities or ASA scores
greater than two. Studies chose the dose of dexmedetomidine based on previous studies
and if a regional anesthetic was used. But no study had great rationale for choice of rapid
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bolus dosing, slow bolus dosing, no bolus, bolus and infusion, and intranasal
administration of dexmedetomidine. This suggests the need for more research to evaluate
the most effective administration route for all pediatric patients. The PAED scale was not
used in all five studies; this suggest the need for more research on the use of the PAED as
a standardized tool. Research on the use of dexmedetomidine and pediatric emergence
agitation has the potential to improve patient care, patient quality, patient safety, and
patient and family satisfaction. Although more research is needed, this systematic review
can provide information to help prevent, treat, and diagnose the patient with emergence
agitation.
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Appendix A
Table A-1
Data Collection Table: Study Demographics and Methods
Kim, N. Y., Kim, S. Y., Yoon, H. J., & Kil, H. K. (2014). Effect of dexmedetomidine on
sevoflurane requirements and emergence agitation in children undergoing ambulatory
surgery. Yonsei Medical Journal, 55(1), 209. doi: 10.3349/ymj.2014.55.1.209
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Di, M., Han, Y., Yang, Z., Liu, H., Ye, X., Lai, H., … Lian, Q. (2017). Tracheal extubation in
deeply anesthetized pediatric patients after tonsillectomy: a comparison of high-concentration
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Chen, F., Wang, C., Lu, Y., Huang, M., & Fu, Z. (2018). Efficacy of different doses of
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Purpose
Design
Sample
Surgical
Method
Procedure
To determine
Double blind
100 patients
Elective
Heart rate, blood
efficacy of
prospective study ASA 1 or 2
inguinal
pressure, SaO2
different doses of Group D1 =
Aged 3-7 years hernia repair
assessed
dexmedetomidine received saline
old
immediately after
as a rapid bolus
Normal
dose, and every
for children to
Group D2 = 0.25 intelligence,
five minutes after.
prevent and treat mcg/kg of
liver, kidney
EA and pain
EA.
dexmedetomidine function
assessed in PACU.
No history of
PAED scale used.
Group D3 = 0.5
allergy to
mcg/kg of
anesthesia
dexmedetomidine
Group D4 = 0.75
mcg/kg of
dexmedetomidine
Group D5 = 1
mcg/kg of
dexmedetomidine

62
Table A-4
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Appendix B
Table B-1
Data Collection Table: Outcome of the Study
Kim, N. Y., Kim, S. Y., Yoon, H. J., & Kil, H. K. (2014). Effect of dexmedetomidine on
sevoflurane requirements and emergence agitation in children undergoing ambulatory
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Table B-2
Data Collection Table: Outcome of the Study
Di, M., Han, Y., Yang, Z., Liu, H., Ye, X., Lai, H., … Lian, Q. (2017). Tracheal extubation in
deeply anesthetized pediatric patients after tonsillectomy: a comparison of high-concentration
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Adverse Side Effects
Limitations
Dose
Group D0
Group D0 6% had EA
Group D0 and D2 had
Plasma
received IV
Group D1 0% had EA
longest time to
concentration of
saline. Group D1 Group D2 0% had EA
discharge Group D0
dexmedetomidine
received
P= 0.05
33.7% and Group D2
was not monitored.
dexmedetomidine
32.8%
This means the
1 mcg/kg. Group
Group D1 only at 25.5% correlation between
D 2 received
length and how
dexmedetomidine
deep the sedation
2 mcg/kg 10
was and
minutes before
hemodynamic
anesthesia.
changes of
dexmedetomidine
in blood could not
be determined.
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Table B-3
Data Collection Table: Outcome of the Study
Chen, F., Wang, C., Lu, Y., Huang, M., & Fu, Z. (2018). Efficacy of different doses of
dexmedetomidine as a rapid bolus for children: a double-blind, prospective, randomized
study. BMC Anesthesiology, 18(1). doi: 10.1186/s12871-018-0562-0
Dexmedetomidine Efficacy
Adverse Side Effects
Limitations
Dose
Group D1
Group D4 (0.75mcg/kg) Group D1 0%
Small sample size.
saline solution
0% incidence of EA
Group D2 5%
Group D2
Group D 5
bradycardia
0.25mcg/kg
(1 mcg/kg) 0%
Group D3 15%
dexmedetomidine incidence of EA
bradycardia
IV bolus
Both groups
Group D4 10%
Group D3
demonstrated
bradycardia
0.5 mcg/kg
significantly reduced
Group D5 10%
dexmedetomidine incidence of EA, fewer
bradycardia
IV bolus
trends noted in D2 and
Group D 4
D3.
0.75 mcg/kg
Group D5 (0%, P <
dexmedetomidine 0.001)
IV bolus
Group D4 (0%, P <
Group D5 1
0.001) Group D3 (5%,
mcg/kg
P= 0.096) Group D2
dexmedetomidine (5%, P=0.096).
IV bolus
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Table B-4
Data Collection Table: Outcome of the Study
He, L., Wang, X., Zheng, S., & Shi, Y. (2013). Effects of dexmedetomidine infusion on
laryngeal mask airway removal and postoperative recovery in children anaesthetized with
sevoflurane. Anaesthesia and Intensive Care, 41(3), 328–333. Doi:
10.1177/0310057x1304100309
Dexmedetomidine Efficacy
Adverse Side Effects
Dose
Group C received The MAC of
Emergence time
Surgeries were less
saline, Group D1 sevoflurane was lower
prolonged in Group
than one hour.
received 0.5
in Group D2 compared
D2(8+3 minutes) and in General anesthesia
mcg/kg
to Group D1, which
Group C (8+3 minutes) was combined with
dexmedetomidine, both were compared to
Recovery time
either local
Group D 2
Group C.
prolonged in Group D2 anesthesia or an
received 1 mcg/kg Group D1 had lower
and Group C (15+6
anesthetic block.
dexmedetomidine emergence agitation
minutes). Hemodynamic Unclear if smaller
after LMA
(17%, P=0.179), Group effects seen with higher doses of
insertion.
D 2 (6%, P=0.179),
doses 1 mcg/kg, but did dexmedetomidine
Group C (42%,
not exceed 20% of the
on an infusion
P=0.003).
values before
pump would have
dexmedetomidine
been more
infusion.
beneficial
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Table B-5
Lin, Y., Chen, Y., Huang, J., Chen, H., Shen, W., Guo, W., … Gan, X. (2016). Efficacy of
premedication with intranasal dexmedetomidine on inhalational induction and postoperative
emergence agitation in pediatric undergoing cataract surgery with sevoflurane. Journal of
Clinical Anesthesia, 33, 289–295. doi: 10.1016/j.jclinane.2016.04.027
Dexmedetomidine Efficacy
Adverse Side Effects
Limitations
Dose
Group C received Intranasal dex greatly
Reduction in heart rates, Influence of the
saline. Group D1 reduced emergence
but did not require
resistance of mask
received 1 mcg/kg agitation.
interventions.
induction on
and diluted with
Group D1 23.3%, P <
emergence
equal volume of
0.001
agitation.
saline. Group D2 Group D2 10% P <
received 2 mcg/kg 0.001
No dose-dependent
of
Group C 80%
effects of dex,
dexmedetomidine
unsure of intranasal
and was not
Emergence and PACU
route due to lack of
diluted.
time all remained the
knowledge of
same between the 3
bioavailability .
groups.
Intranasal dex improved
mask induction.
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Appendix C
Table C-1
Critical Appraisal for Summaries of Evidence (CASE) Worksheet
Kim, N. Y., Kim, S. Y., Yoon, H. J., & Kil, H. K. (2014). Effect of dexmedetomidine
on sevoflurane requirements and emergence agitation in children undergoing
ambulatory surgery. Yonsei Medical Journal, 55(1), 209. doi:
10.3349/ymj.2014.55.1.209
Questions
Evaluations
Summary Topic
1.) Is the summary specific in scope and
Yes: X
application
Not Completely:
No:
Summary Methods
2.) Is the authorship of the summary
Yes: X
transparent?
Not Completely:
No:
3.) Are the reviewers/editors of the
Yes: X
summary transparent
Not Completely:
No:
4.) Are the research methods
Yes: X
transparent and comprehensive?
Not Completely:
No:
5.) Is the evidence grading system
Yes:
transparent and translatable?
Not Completely: X
No:
Summary Content
6.) Are the recommendations clear?
Yes: X
Not Completely:
No:
7.) Are the recommendations
Yes: X
appropriately cited?
Not Completely:
No:
8.) Are the recommendations current?
Yes: X
Not Completely:
No:
9.) Is the summary unbiased?
Yes: X
Not Completely:
No:
Summary Application
10.) Can this summary be applied to your Yes: X
patients ?
Not Completely:
No:
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Table C-2
Critical Appraisal for Summaries of Evidence (CASE) Worksheet
Di, M., Han, Y., Yang, Z., Liu, H., Ye, X., Lai, H., … Lian, Q. (2017). Tracheal
extubation in deeply anesthetized pediatric patients after tonsillectomy: a
comparison of high-concentration sevoflurane alone and low-concentration
sevoflurane in combination with dexmedetomidine pre-medication. BMC
Anesthesiology, 17(1). doi: 10.1186/s12871-017-0317-3
Questions
Evaluations
Summary Topic
1.) Is the summary specific in scope
Yes: X
and application
Not Completely:
No:
Summary Methods
2.) Is the authorship of the summary
Yes: X
transparent?
Not Completely:
No:
3.) Are the reviewers/editors of the
Yes: X
summary transparent
Not Completely:
No:
4.) Are the research methods
Yes: X
transparent and comprehensive?
Not Completely:
No:
5.) Is the evidence grading system
Yes: X
transparent and translatable?
Not Completely:
No:
Summary Content
6.) Are the recommendations clear?
Yes: X
Not Completely:
No:
7.) Are the recommendations
Yes: X
appropriately cited?
Not Completely:
No:
8.) Are the recommendations
Yes: X
current?
Not Completely:
No:
9.) Is the summary unbiased?
Yes: X
Not Completely:
No:
Summary Application
10.) Can this summary be applied to
Yes: X
your patients ?
Not Completely:
No:
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Table C-3
Critical Appraisal for Summaries of Evidence (CASE) Worksheet
Chen, F., Wang, C., Lu, Y., Huang, M., & Fu, Z. (2018). Efficacy of different
doses of dexmedetomidine as a rapid bolus for children: a double-blind,
prospective, randomized study. BMC Anesthesiology, 18(1). doi:
10.1186/s12871-018-0562-0
Questions
Evaluations
Summary Topic
1.) Is the summary specific in scope
Yes: X
and application
Not Completely:
No:
Summary Methods
2.) Is the authorship of the summary
Yes: X
transparent?
Not Completely:
No:
3.) Are the reviewers/editors of the
Yes: X
summary transparent
Not Completely:
No:
4.) Are the research methods
Yes: X
transparent and comprehensive?
Not Completely:
No:
5.) Is the evidence grading system
Yes:
transparent and translatable?
Not Completely: X
No:
Summary Content
6.) Are the recommendations clear?
Yes: X
Not Completely:
No:
7.) Are the recommendations
Yes: X
appropriately cited?
Not Completely:
No:
8.) Are the recommendations
Yes: X
current?
Not Completely:
No:
9.) Is the summary unbiased?
Yes:
Not Completely: X
No:
Summary Application
10.) Can this summary be applied to
Yes: X
your patients ?
Not Completely:
No:
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Table C-4
Critical Appraisal for Summaries of Evidence (CASE) Worksheet
He, L., Wang, X., Zheng, S., & Shi, Y. (2013). Effects of Dexmedetomidine
Infusion on Laryngeal Mask Airway Removal and Postoperative Recovery in
Children Anaesthetized with Sevoflurane. Anaesthesia and Intensive
Care, 41(3), 328–333. doi: 10.1177/0310057x1304100309
Questions
Evaluations
Summary Topic
1.) Is the summary specific in scope
Yes: X
and application
Not Completely:
No:
Summary Methods
2.) Is the authorship of the summary
Yes: X
transparent?
Not Completely:
No:
3.) Are the reviewers/editors of the
Yes: X
summary transparent
Not Completely:
No:
4.) Are the research methods
Yes:
transparent and comprehensive?
Not Completely: X
No:
5.) Is the evidence grading system
Yes:
transparent and translatable?
Not Completely: X
No:
Summary Content
6.) Are the recommendations clear?
Yes: X
Not Completely:
No:
7.) Are the recommendations
Yes: X
appropriately cited?
Not Completely:
No:
8.) Are the recommendations
Yes: X
current?
Not Completely:
No:
9.) Is the summary unbiased?
Yes: X
Not Completely:
No:
Summary Application
10.) Can this summary be applied to
Yes: X
your patients ?
Not Completely:
No:
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Table C-5
Critical Appraisal for Summaries of Evidence (CASE) Worksheet
Lin, Y., Chen, Y., Huang, J., Chen, H., Shen, W., Guo, W., … Gan, X. (2016).
Efficacy of premedication with intranasal dexmedetomidine on inhalational
induction and postoperative emergence agitation in pediatric undergoing cataract
surgery with sevoflurane. Journal of Clinical Anesthesia, 33, 289–295. doi:
10.1016/j.jclinane.2016.04.027
Questions
Evaluations
Summary Topic
1.) Is the summary specific in scope
Yes: X
and application
Not Completely:
No:
Summary Methods
2.) Is the authorship of the summary
Yes: X
transparent?
Not Completely:
No:
3.) Are the reviewers/editors of the
Yes: X
summary transparent
Not Completely:
No:
4.) Are the research methods
Yes:
transparent and comprehensive?
Not Completely: X
No:
5.) Is the evidence grading system
Yes: X
transparent and translatable?
Not Completely:
No:
Summary Content
6.) Are the recommendations clear?
Yes: X
Not Completely:
No:
7.) Are the recommendations
Yes: X
appropriately cited?
Not Completely:
No:
8.) Are the recommendations
Yes: X
current?
Not Completely:
No:
9.) Is the summary unbiased?
Yes: X
Not Completely:
No:
Summary Application
10.) Can this summary be applied to
Yes: X
your patients ?
Not Completely:
No:
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Appendix D
Table 5
Cross Study Analysis Tool
Study EA
ASA / Patient
#
Characteristics
1
Group D 5% ASA 1
Kim
vs Group S
Ages 1-5
et al. 55%
Hernioplasty or
Orchiopexy
surgery
2
Group D0
Seventy-five
Di et 6% had EA
patients. ASA 1
al.
Group D1
or 2. Aged 3-7
0% had EA
years old.
Group D2
Tonsillectomy
0% had EA
P= 0.05
3
Dex infused
100 patients.
Chen at 0.75
ASA 1 or 2,
et al. (Group D4)
aged 3-7 years
and 1.0
old, normal
mcg/kg
intelligence,
(group D5)
liver, kidney
prevents EA. function. No
Group D5
history of
(0%, P <
allergy to
0.001)
anesthesia.
Group D4
Elective
(0%, P <

Anesthetic

Dexmedetomidine
dose
D= 1mcg/kg bolus
followed infusion of
0.1mcg/kg/hr
S= saline

Hypotension/
Bradycardia
+
22-26%

Sevoflurane

D0= NS
D1 = 1mcg/kg bolus
of dex
D2 = 2mcg/kg bolus

No interventions
needed

Recovery time was
longest in Group D2.
Group D1 had shortest
recovery time.

Sevoflurane

D1 =
saline
D2 = 0.25mcg/kg
dexmedetomidine IV
bolus
D3 =
0.5 mcg/kg
dexmedetomidine IV
bolus
D4=

No interventions
for hypotension.
Group D1 0%
Group D2 5%
bradycardia
Group D3 15%
bradycardia
Group D4 10%
bradycardia
Group D5 10%

N/A

Sevoflurane
Caudal
Block

Ilioinuguina
l/iliohypoga
stric nerve
block

LOS
No delays in same day
discharge noted.

+ 18-21%

75
0.001) Group Inguinal hernia
D3 (5%, P=
repair surgery.
0.096) Group
D2 (5%,
P=0.096).
4
He et
al.

Group D1
had lower
emergence
agitation
(17%),
Group D 2
(6%), Group
C (42%).

0.75 mcg/kg
dexmedetomidine IV
bolus
D5 = 1 mcg/kg
dexmedetomidine IV
bolus

Eighty-Seven
patients.
ASA 1 or 2.
Aged 3-7 years
old.
Minor surface
surgeries

Sevoflurane

C = saline, D1 = 0.5
mcg/kg
dexmedetomidine
D 2 = 1 mcg/kg
dexmedetomidine

5
Intranasal
Ninety ASA 1
Lin et dex greatly
and 2 for
al.
reduced
cataract surgery
emergence
agitation.
Group D1
7/30 patients,
Group D2
2/30, Group
C 24/30.

Sevoflurane

C = saline. D1 = 1
mcg/kg
dexmedetomidine
D2 = received 2
mcg/kg of
dexmedetomidine

0.5%
proparacain
e eye drops

Hemodynamic
effects seen with
higher doses 1
mcg/kg, but did
not exceed 20%
of the values
before
dexmedetomidine
infusion
No interventions
Reduction in
heart rates, but
did not require
interventions.

Emergence time
prolonged in Group
D2(8+3 minutes) and in
Group C (8+3 minutes)
Recovery time prolonged
in Group D2 and Group
C (15+6 minutes).
Emergence and PACU
time all remained the
same between the 3
groups

